news
FDA begins rolling back decades of hormone therapy warnings
On February 12, the FDA began stripping parts of its long-standing boxed warning from menopausal hormone therapy. The black-box label had stood for over twenty years following flawed interpretations of the 2002 Women's Health Initiative trial. The shift clears an outdated hurdle for clinicians treating perimenopausal sleep disruption, vasomotor symptoms, and bone density loss.
On February 12, the FDA began stripping parts of its long-standing boxed warning from menopausal hormone therapy. The black-box label had stood for over twenty years following flawed interpretations of the 2002 Women's Health Initiative trial. The shift clears an outdated hurdle for clinicians treating perimenopausal sleep disruption, vasomotor symptoms, and bone density loss.
The architecture take
I watched clinicians treat hormone therapy like contraband for over a decade, terrified by skewed headlines from the 2002 Women's Health Initiative. When estrogen drops in perimenopause, your brain thermoregulation misfires, slow-wave sleep fragments, and cortisol spikes at 3 a.m. just to keep up. For twenty-four years, the FDA slapped its most aggressive boxed warning on systemic estrogen and progesterone. That label scared millions of women away from reliable relief for night sweats, mood drops, and rapid bone loss. The agency is finally walking parts of that warning back. Provider habit dies hard. Longevity startups already charge $3,000 a year to mail bioidentical estradiol and micronised progesterone to your door. Watch whether general practitioners actually start writing these prescriptions now, or if hormonal baseline support remains an expensive boutique perk.